Nothing can kill a healthcare’s stock price like a failed clinical trial. Just take a look at the disaster that’s befallen Vical Incorporated …
Vical Incorporated (NASDAQ:VICL) announced that the last patient completed their final assessment during the one year follow-up period in the multinational Phase 3 …
It has been an explosive twenty-four hours in the biotech-verse, as analysts are prompted to offer insights on Sarepta Therapeutics Inc (NASDAQ:SRPT), with shares shooting …
Vical Incorporated (NASDAQ:VICL) announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating the safety and efficacy of cytomegalovirus (CMV) vaccine, …
Vical Incorporated (NASDAQ:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, announced that the U.S.
Vical Incorporated (NASDAQ:VICL) reported financial results for the three and nine months ended September 30, 2015. Net loss for the third quarter of 2015 …
Vical Incorporated (NASDAQ:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, today announced that the Company will present …
Vical Incorporated (NASDAQ:VICL), a biotechnology company developing vaccines and therapeutics for prevention and treatment of infectious diseases, today announced that the U.S.
Vical Incorporated (NASDAQ:VICL) shares are tumbling 42.85% to $0.
Roth Capital analyst Debjit Chattopadhyay came out with a research note on Vical Incorporated (NASDAQ:VICL), as the company is expected to release top-line …